CHARLESTON, S.C., August, 2025 – Afaxys, Inc., a socially conscious healthcare company focused on serving the reproductive health needs of public health professionals and their patients, announces it has secured $8 million in new funding from two large foundations to support its mission and propel its growth strategy. The capital includes a $3 million program-related investment (PRI) from the David and Lucile Packard Foundation and a $5 million grant from an anonymous foundation. This marks the third investment from the Packard Foundation since Afaxys was founded in 2008, underscoring the long-standing partnership and confidence in Afaxys’ impact-driven model. “Through our mission-based investments, Afaxys has grown into a durable and financially sustainable force in the market that will continue to actively ensure and continually expand reproductive health access for all patients, especially those served by public health providers,” said Susan Phinney-Silver, Mission Investing Director at the David and Lucile Packard Foundation.
The new funding serves as a catalyst for growth as Afaxys continues its mission of providing millions of women in the United States access to affordable contraception. Afaxys is the only organization of its kind with an established, nationwide distribution infrastructure serving public health clinics. Afaxys plays a critical role in ensuring reliable supply chains for clinics that serve Medicaid and Title X patients. The funding will be used to complete the development of a novel contraceptive product, specifically designed to address the needs of marginalized communities and the more than 19 million women living in contraceptive deserts. “Access to quality reproductive healthcare has never been more critical. We are excited to partner with these esteemed foundations to further the Afaxys mission and ensure that access to reproductive healthcare is a right, not a privilege,” said Ronda Dean, CEO of Afaxys, Inc.
About Afaxys
Afaxys, a Public Benefit Corporation, uniquely partners with public health and private industry to ensure healthcare professionals have stable pricing and reliable access to the products and services they need to care for their patients.
The Afaxys enterprise comprises a family of companies that operate under three wholly owned subsidiaries: Afaxys Pharma, LLC, Afaxys Drug Development, LLC and Afaxys Group Services, LLC (AGS). Afaxys Pharma provides a broad portfolio of branded and generic contraceptives to the public healthcare market. Afaxys Drug Development provides development and regulatory services of pharmaceutical products with a focus on rapid and efficient launch readiness to promote Afaxys’ strategic goal of cost-conscious product commercialization. AGS is a strategic sourcing operation that negotiates favorable pricing across a broad base of products and services through its Group Purchasing Organization. For more information, visit www.afaxys.com.
Forward-Looking Statements
The statements in this press release that are not historical facts constitute “forward-looking statements” as defined by Federal Securities laws. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, risks related to the inability to implement strategic initiatives, and the dependence on key personnel. Forward-looking statements speak only as of the date they are made. Afaxys, Inc. will not update forward-looking statements to reflect factual assumptions, circumstances or events that have changed after a forward-looking statement was made.
Afaxys Media Contact
Green Room Communications
gr_afaxys@grcomms.com